The global Hereditary Testing Market size is expected to reach USD 13.6 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.2% from 2022 to 2030. Key factors driving the market are the declining cost of sequencing and the availability of genetic tests at a lower price. Furthermore, the availability of niche and fragmented point solutions across the genomics value chain, namely sequencing, analytics, interpretation, aggregation, and marketplace, is anticipated to propel the market growth over the forecast period.
The advent of direct-to-consumer genetics
is anticipated to play a major role in the genetic testing market by enabling
individuals to carry out self-testing. This expands the role of genetic
counselors, which further aids in understanding the importance of genetic tests
and helps in the selection of appropriate tests. A growing number of registered
genetic counselors is anticipated to boost the adoption of hereditary genetic
tests in the coming years.
Another important market trend is the
growing field of reproductive genetic health. For instance, Natera has seen a
consistent increase in test numbers in hereditary illnesses genetic analysis
for women's health. This indicates a rise in public acceptance of hereditary
testing, which is fueling the market expansion. A rise in the trade of newborn
screening equipment has corresponded with a rise in the trade of DNA experiment
equipment. Progressing the sharpness of newborn screening all over the world is
also assisting in earnings increase. A multigene board trial was formed for
introducing genetic melanoma into the clinical application, which has been
prompted by changes in genetic experimentation standards. The growing
generative hereditary health scope is one of the most important key factors
driving the market.
The COVID-19 pandemic had a detrimental
impact on the market. For example, after the World Health Organization declared
COVID-19 a pandemic, governments all around the world used lockdowns to compel
social distancing as a prophylactic measure. In every industry, this resulted
in upheaval, constraints, challenges, and adjustments. Similarly, the outbreak
has a negative impact on the inherited genetic analysis sector.
Technology developers are introducing
advanced products to enhance the efficiency of genetic tests by diagnostic
companies. For example, in December 2020, the QuantiFERON SARS-CoV-2 RUO
solution was introduced by QIAGEN, a business that provides technologies and
products for pre-analytical samples and related molecular test solutions. The
solution detects immune system T-cell responses to the infection that causes
COVID-19. The solution would give precise information on illness development
and immunity levels.
Related Press Release@ Hereditary
Testing Market Report
Hereditary
Testing Market Report Highlights
- The hereditary cancer testing disease type segment
is expected to expand at a considerable rate over the forecast period. A
substantial number of CLIA-certified laboratories perform tests to
determine whether an individual carries an inherited mutated gene that can
cause cancer
- The breast cancer testing segment dominated the
hereditary cancer testing market in 2021 owing to its high penetration and
increased inheritability. Most of the cases of cervical cancer are
non-hereditary, resulting in the lowest revenue share of this segment
- In the hereditary non-cancer testing disease type
segment, the cardiac diseases segment is driven by the emergence of
high-throughput sequencing, which has resulted in the commercial
availability of a significant number of sequencing assays for
cardiomyopathies
- The Non-invasive Prenatal Testing (NIPT)
and cancer screening tests segment and the newborn genetic screening
segment continue to witness lucrative growth due to the increased adoption
across the globe
- Moreover, the newborn screening program has been
made mandatory in several regions and countries, resulting in the growth
of newborn genetic screening in the hereditary non-cancer testing disease
type segment
- Europe and North America collectively accounted for
over 65.0% share of the overall revenue in 2021 owing to the assisted
reproductive technology space, coupled with the high penetration of
newborn genetic screening
- Key companies are engaged in securing regulatory
approval in emerging countries to expand their business footprint. A
substantial number of diagnostic companies have collaborated with
technology developers to obtain technology licenses and deliver high-value
services to their customers
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment